Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder

 

 Buy Article Permissions and Reprints

Summary

Platelet aggregometry and dense granule adenosine triphosphate (ATP) release assays are helpful to diagnose platelet disorders. Some laboratories simultaneously measure aggregation and ATP release using Chronolume^®, a commercial reagent containing D-luciferin, firefly luciferase and magnesium. Chronolume^® can potentiate sub-maximal aggregation responses, normalising canine platelet disorder findings. We investigated if Chronolume^® potentiates human platelet aggregation responses after observing discrepancies suspicious of potentiation. Among patients simultaneously tested by light transmission aggregometry (LTA) on two instruments, 18/43 (42%), including 14/24 (58%) with platelet disorders, showed full secondary aggregation with one or more agonists only in tests with Chronolume^®. As subjects with Quebec platelet disorder (QPD) did not show the expected absent secondary aggregation responses to epinephrine in tests with Chronolu-me^®, the reason for the discrepancy was investigated using samples from 10 QPD subjects. Like sub-threshold ADP (0.75 μM), Chronolume^® significantly increased QPD LTA responses to epinephrine (p<0.0001) and it increased both initial and secondary aggregation responses, leading to dense granule release. This potentiation was not restricted to QPD and it was mimicked adding 1–2 mM magnesium, but not D-luciferin or firefly luciferase, to LTA assays. Chronolume^® potentiated the ADP aggregation responses of QPD subjects with a reduced response. Furthermore, it increased whole blood aggregation responses of healthy control samples to multiple agonists, tested at concentrations used for the diagnosis of platelet disorders (p values <0.05). Laboratories should be aware that measuring ATP release with Chronolume^® can potentiate LTA and whole blood aggregation responses, which alters findings for some human platelet disorders, including QPD.

• References

• 1 Hayward C P. Diagnostic evaluation of platelet function disorders. Blood Rev 2011; 25: 169-173.
  CrossrefPubMedGoogle Scholar
• 2 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009; 35: 158-167.
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Pai M, Hayward C P. Diagnostic assessment of platelet disorders: what are the challenges to standardization?. Semin Thromb Hemost 2009; 35: 131-138.
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Quiroga T, Goycoolea M, Matus V. et al. Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays. Br J Haematol 2009; 147: 729-736.
  PubMedGoogle Scholar
• 5 Hayward C P, Pai M, Liu Y. et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 07: 676-684.
  CrossrefPubMedGoogle Scholar
• 6 Castilloux JF, Moffat KA, Liu Y. et al. A prospective, cohort study of light transmission platelet aggregometry for bleeding disorders: Is testing native platelet rich plasma non-inferior to testing platelet count adjusted samples?. Thromb Haemost 2011; 106: 675-682.
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Pai M, Wang G, Moffat KA. et al. Diagnostic usefulness of a lumiaggregometer adenosine triphosphate release assay for the assessment of platelet function disorders. Am J Clin Pathol 2011; 136: 350-358.
  CrossrefPubMedGoogle Scholar
• 8 Cattaneo M, Hayward C P, Moffat KA. et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 07: 1029.
  CrossrefPubMedGoogle Scholar
• 9 Christie DJ, Avari T, Carrington LR. et al. Clinical and Laboratory Standards Institute (CLSI). Platelet function testing by aggregometry; approved guideline. CLSI document H58-A (ISBN 1-56238-683-2). Clinical and Laboratory Standards Institute. Wayne, PA, USA: 2008 28. 31 Available at: http://www.clsi.org Assessed May 31, 2011.
  PubMedGoogle Scholar
• 10 McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Haemost 2009; 35: 168-180.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Callan MB, Shofer Frances S. et al. Chrono-lume^® and magnesium potentiate aggregation of canine but not human platelets in citrated platelet-rich plasma. Thromb Haemost 1998; 80: 176-180.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Mehta P, Mehta JL, Aguila E. Platelet aggregation. Blood 1983; 62: 1151.
  PubMedGoogle Scholar
• 13 Mehta P, Mehta J, Ostrowski N. et al. Potentiation of platelet aggregation by CHRONOLUME^® . Thromb Res 1983; 32: 509-512.
  CrossrefPubMedGoogle Scholar
• 14 Hayward C P, Moffat KA, Raby A. et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134: 955-963.
  CrossrefPubMedGoogle Scholar
• 15 Hayward C P, Rivard GE. Quebec platelet disorder. Expert Rev Hematol 2011; 04: 137-141.
  CrossrefPubMedGoogle Scholar
• 16 Blavignac J, Bunimov N, Rivard GE. et al. Quebec platelet disorder: Update on pathogenesis, diagnosis and treatment. Semin Thromb Haemost 2011; 37: 713-720.
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Paterson AD, Rommens JM, Bharaj B. et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010; 115: 1264-1266.
  CrossrefPubMedGoogle Scholar
• 18 Hayward C P, Moffat KA, Pai M. et al. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thromb Haemost 2008; 100: 134-145.
  PubMedGoogle Scholar
• 19 Thompson NT, Scrutton MC. Inhibition by luciferin-luciferase reagents of aggregation responses to excitatory agonists in washed platelet suspensions. Thromb Res 1985; 28: 109-119.
  PubMedGoogle Scholar
• 20 Noda L, Nihei T, Morales MF. The enzymatic activity and inhibition of adenosine 5'-triphosphate-creatine transphosphorylase. J Biol Chem 1960; 235: 2830-2834.
  PubMedGoogle Scholar
• 21 Pesho MM, Bledzka K, Michalec L. et al. The specificity and function of the metal-binding sites in the integrin beta3 A-domain. J Biol Chem 2006; 281: 23034-23041.
  CrossrefPubMedGoogle Scholar
• 22 Yamniuk A P, Vogel HJ. Calcium- and magnesium-dependent interactions between calcium- and integrin-binding protein and the integrin alphaIIb cytoplasmic domain. Protein Sci 2005; 16: 1429-1437.
  PubMedGoogle Scholar
• 23 Yamniuk A P, Nguyen LT, Hoang T T. et al. Metal ion binding properties and conformational states of calcium- and integrin-binding protein. Biochemistry 2004; 43: 2558-2568.
  CrossrefPubMedGoogle Scholar
• 24 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 03: 135-158.
  CrossrefPubMedGoogle Scholar
• 25 Ingerman-Wojenski CM, Silver MJ. A quick method for screening platelet dysfunctions using the whole blood-aggregometer. Thromb Haemost 1984; 51: 154-156.
  PubMedGoogle Scholar